RxDoctor Payments Data

Ali Mainayar

Optometrist · Renton, WANPI 1013570381

Payments from drug & device makers

$2,512in general payments, 2019–2025

Across 93 payments — averaging $27.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$486
  • AbbVie$461
  • Alcon$398
  • Biotissue Holdings Inc.$249
  • Bausch & Lomb Americas Inc.$230
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$125
  • plus $563 from 11 others

What the payments were for

  • Food & beverage$2,512100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,512 in reported general payments places this provider in the 85th percentile of 1,267 optometrist providers in Washington.

See all optometrist providers in Washington

Medicare billing

Part B allowed, 2024
$70,404
Medicare patients
262
Services billed
767

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine28$39,017
LumiganBimatoprost31$18,528
CequaCyclosporine12$16,262
SimbrinzaBrinzolamide/Brimonidine Tart20$6,376
Prednisolone Acetate91$3,973
Latanoprost477$3,874
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol19$2,011
Travoprost19$1,894
Brimonidine Tartrate109$1,523
Difluprednate18$1,428
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat146$1,404
Timolol Maleate146$1,151
Dorzolamide Hcl39$844
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha12$104

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$461$57,54559 claims
Sun Pharmaceutical Industries Inc.Cequa$486$16,26212 claims
AlconSimbrinza$398$6,37620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,267 optometrist providers in Washington.

Other optometrist in Renton

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →